Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17746918 | 0.91 | HMGCR (0.78) | HMGCRCYP3A4KMT2AMEN1HTT | |
| SCHEMBL8893882 | 0.86 | HMGCR (0.56) | HMGCRCYP3A4KMT2AMEN1PAX8 | |
| SCHEMBL22840674 | 0.86 | HMGCR (0.77) | HMGCRCYP3A4KMT2AMEN1HTT | |
| SCHEMBL11342543 | 0.86 | HMGCR (0.61) | HMGCRCYP3A4KMT2AMEN1HTT | |
| SCHEMBL7460397 | 0.85 | CYP3A4 (0.59) | HMGCRCYP3A4KMT2AMEN1PAX8 | |
| SCHEMBL27675292 | 0.85 | HMGCR (0.54) | HMGCRCYP3A4KMT2AMEN1 | |
| SCHEMBL8895935 | 0.85 | HMGCR (0.54) | HMGCRCYP3A4ALDH1A1GAA | |
| SCHEMBL13284211 | 0.84 | HMGCR (0.68) | HMGCRCYP3A4KMT2AMEN1HTT | |
| SCHEMBL27997509 | 0.84 | HMGCR (0.57) | HMGCRCYP3A4KMT2AMEN1PAX8 | |
| SCHEMBL9720676 | 0.84 | HMGCR (0.58) | HMGCRCYP3A4KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025234-A | Synthesis method of alpha-asarone | 湖南威特制药股份有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-110128248-A | It is a kind of green simplicity prepare alpha-ararin technique | 承德石油高等专科学校 | 2019-08-16 | — | — | CN | claimed |
| CN-102199077-B | Method for producing (E)-2,4,5-trimethoxy-1-propenylbenzene | LU CHAO | 2013-01-23 | — | — | CN | claimed |
| CN-102199077-A | Method for producing (E)-2,4,5-trimethoxy-1-propenylbenzene | CHAO LU | 2011-09-28 | — | — | CN | claimed |
| CN-101891604-A | Method for synthesizing 2,4,5-trimethoxyethylphenylketone intermediate of alpha-asarin | GUANGXI TRADITIONAL CHINESE MEDICAL UNIVERSITY | 2010-11-24 | — | — | CN | claimed |
| CN-101195562-A | Novel method for synthesizing alpha-asarone | GUANGXI TRADITIONAL CHINESE ME (CN) | 2008-06-11 | — | — | CN | claimed |
| EP-1487770-B1 | FORMATION OF NEOLIGNAN BY DDQ MEDIATED DIMERISATION OF DIHYDROASARONE | COUNCIL SCIENT IND RES (IN) | 2007-12-12 | — | — | EP | claimed |
| US-6969778-B2 | DDQ mediated one step dimerization of β-asarone or β-asarone rich Acorus calamus oil in the formation of novel neolignan | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-11-29 | — | — | US | claimed |
| US-20040049085-A1 | DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2004-03-11 | — | — | US | claimed |
| WO-2003082786-A1 | A PROCESS FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE ALPHA-ASARONE FROM TOXIC BETA-ASARONE RICH ACORUS CALAMUS OIL | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-10-09 | — | — | WO | claimed |
| US-6590127-B1 | Formation of alpha-asarone, isoacoramone and 2,4,5-trimethoxycinnamaldehyde in one step process via 2,3-dichloro-5,6-dicyano-1,4-benzoquinone assisted dehydrogenation/oxidation of 2,4,5-trimethoxyphenylpropane | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2003-07-08 | — | — | US | claimed |
| CN-120025234-A | Synthesis method of alpha-asarone | 湖南威特制药股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-120025234-A | Synthesis method of alpha-asarone | 湖南威特制药股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-110183431-A | One kind is for liver disease or the compound of prevention | 江苏新元素医药科技有限公司 | 2019-08-30 | — | — | CN | disclosed |
| CN-110128248-A | It is a kind of green simplicity prepare alpha-ararin technique | 承德石油高等专科学校 | 2019-08-16 | — | — | CN | disclosed |
| US-20030113275-A1 | Process for the preparation of 1-Propyl-2, 4, 5- trimethoxybenzene from toxic beta-asarone of Acorus calamus or from crude calamus oil containing beta-asarone | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2003-06-19 | — | — | US | disclosed |
| US-6528041-B2 | Organoleptic | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-03-04 | — | — | US | disclosed |
| US-20020035299-A1 | Process for the preparation of 1-Propyl-2, 4, 5-trimethoxybenzene from toxic beta-asarone of acorus calamus or from crude calamus oil containing beta-asarone | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2002-03-21 | — | — | US | disclosed |
| US-5952355-A | 1-ETHER-SUBSTITUTED PHENYL-3-INDOL-3-YL-2-PROPEN-1-ONE DERIVATIVES; ANTITUMOR AND -CARCINOGENIC AGENTS; IMMUNOSUPPRESSANTS; AUTOIMMUNE DISEASES; SIDE EFFECT REDUCTION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0770601-A1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049085-A1 | DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan | DHPS, PTGES, PTGIS | HMGCR 467/4885CYP3A4 254/4885KMT2A 2954/4885 |
| US-20020035299-A1 | Process for the preparation of 1-Propyl-2, 4, 5-trimethoxybenzene from toxic beta-asarone of acorus calamus or from crude calamus oil containing beta-asarone | ADRA2B, CYP1B1, ADRB1 | HMGCR 365/4885CYP3A4 47/4885KMT2A 3577/4885 |
| US-20030113275-A1 | Process for the preparation of 1-Propyl-2, 4, 5- trimethoxybenzene from toxic beta-asarone of Acorus calamus or from crude calamus oil containing beta-asarone | ADRA2B, CYP1B1, ADRB1 | HMGCR 348/4885CYP3A4 46/4885KMT2A 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.